Image

    Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata

    October 2019 in “ Dermatology and therapy ”
    Ana Montilla, Francisco Gómez-García, Pedro Jesús Gómez-Arias … Juan Ruano
    Studysummary This review found that JAK/STAT pathway inhibitors, such as tofacitinib and ruxolitinib, led to symptom improvement in all observed atopic dermatitis cases, but responses were mixed for vitiligo and alopecia areata, with a generally mild safety profile reported.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 69

    1. The Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata: A Systematic Review Dermatologic therapy · 2019
    2. Alopecia Universalis: Partial Response to Tofacitinib Medicina Clínica (English Edition) · 2019
    3. Drugs Targeting the JAK/STAT Pathway for the Treatment of Immune-Mediated Inflammatory Skin Diseases: Protocol for a Scoping Review BMJ Open · 2019
    4. Alopecia Areata Lesions Show Significant Changes In Immune And Keratin Biomarkers That Correlate With Clinical Improvement With Oral Janus Kinase Inhibitors PF-06651600 (JAK3) And PF-06700841 (TYK2/JAK1) Journal of Investigative Dermatology · 2019
    5. Janus Kinase Inhibition in Down Syndrome: Two Cases of Therapeutic Benefit for Alopecia Areata JAAD case reports · 2019
    6. JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2019
    7. Clinical Experiences on Alopecia Areata Treatment with Tofacitinib: A Study of 63 Patients Dermatologic Therapy · 2019
    8. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature Journal of cutaneous medicine and surgery · 2019
    9. Tofacitinib Therapy for Children with Severe Alopecia Areata Journal of the American Academy of Dermatology · 2019
    10. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study Dermatology · 2018
    11. Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata Journal of the European Academy of Dermatology and Venereology · 2018
    12. Topical Tofacitinib Solution for the Treatment of Alopecia Areata Affecting Eyelashes JAAD Case Reports · 2018
    13. Alopecia Universalis and Chronic Graft-Versus-Host Disease Treated With Ruxolitinib JAMA Dermatology · 2018
    14. Therapeutic Synergy Between Contact Dermatitis from a Wig-Fixing Device and Tofacitinib on Alopecia Areata The Journal of Dermatology · 2018
    15. Ruxolitinib for the Treatment of Severe Alopecia Areata Journal of the American Academy of Dermatology · 2018
    16. Tofacitinib for the Treatment of Alopecia Areata in Preadolescent Children Journal of the American Academy of Dermatology · 2018
    17. Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study International Journal of Dermatology · 2018
    18. Balance of Tofacitinib Efficacy and Disease Flare in the Treatment of Alopecia Universalis: A Case Report and Review of the Literature JAAD Case Reports · 2018
    19. An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review PubMed · 2018
    20. JAK Inhibitors for Treatment of Alopecia Areata ˜The œjournal of investigative dermatology/Journal of investigative dermatology · 2018
    21. Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata Drug design, development and therapy · 2018
    22. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018
    23. Simultaneous Improvement of Alopecia Universalis and Atopic Dermatitis in a Patient Treated with a JAK Inhibitor JAAD case reports · 2018
    24. Topical 2% Tofacitinib for Children with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Journal of the American Academy of Dermatology · 2018
    25. Molecular Correlation With Clinical Outcomes in an Open Label Clinical Trial of Oral Tofacitinib in Patients With Alopecia Areata Journal of Investigative Dermatology · 2018
    26. Topical Janus Kinase Inhibitors: A Review of Applications in Dermatology Journal of the American Academy of Dermatology · 2018
    27. Nail Involvement in Patients with Moderate-to-Severe Alopecia Areata Treated with Oral Tofacitinib Journal of Dermatological Treatment · 2018
    28. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
    29. Treatment of Vitiligo with the Topical Janus Kinase Inhibitor Ruxolitinib: A 32-Week Open-Label Extension Study with Optional Narrow-Band Ultraviolet B Journal of the American Academy of Dermatology · 2018
    30. Emerging Drugs for Alopecia Areata: JAK Inhibitors Expert opinion on emerging drugs · 2018
    31. Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients International Journal of Trichology · 2018
    32. Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study Acta dermato-venereologica · 2018
    33. Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients Journal of the American Academy of Dermatology · 2017
    34. Oral Tofacitinib: A Promising Treatment in Atopic Dermatitis, Alopecia Areata, and Vitiligo Clinical and Experimental Dermatology · 2017
    35. Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series Journal of the American Academy of Dermatology · 2017
    36. Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient Skin appendage disorders · 2017
    37. Brazilian Experience of Treating Alopecia Universalis with Novel Antirheumatic Therapy Tofacitinib: A Case Series Rheumatology and Therapy · 2017
    38. A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata Journal of cutaneous medicine and surgery · 2017
    39. Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata Journal of the American Academy of Dermatology · 2017
    40. Successful Hair Regrowth in a Korean Patient with Alopecia Universalis Following Tofacitinib Treatment Singapore Medical Journal · 2017
    41. An Open Label Clinical Trial of the JAK Inhibitor Tofacitinib for Alopecia Areata Journal of Investigative Dermatology · 2017
    42. Treatment of Severe Alopecia Areata with the Oral Janus Kinase Inhibitor, Tofacitinib: A Retrospective Chart Review Journal of Investigative Dermatology · 2017
    43. Treatment of Alopecia Areata With Tofacitinib JAMA Dermatology · 2017
    44. Two Cases of Alopecia Areata Treated with Ruxolitinib: A Discussion of Ideal Dosing and Laboratory Monitoring International Journal of Dermatology · 2017
    45. Experience with Oral Tofacitinib in 8 Adolescent Patients with Alopecia Universalis Journal of the American Academy of Dermatology · 2017
    46. Janus Kinase Inhibitors in Dermatology: A Systematic Review Journal of the American Academy of Dermatology · 2017
    47. JAK Inhibitors in Dermatology: The Promise of a New Drug Class Journal of the American Academy of Dermatology · 2017
    48. Alopecia Universalis Unresponsive to Treatment with Tofacitinib: Report of a Case with a Brief Review of the Literature Dermatology online journal · 2017
    49. Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.) · 2017
    50. Janus Kinase (JAK) Inhibitors for the Treatment of Skin and Hair Disorders: A Review of Literature Journal of Dermatological Treatment · 2016
    51. Reversal of Alopecia Universalis by Tofacitinib: A Case Report Annals of Internal Medicine · 2016
    52. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    53. Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report Case Reports in Dermatology · 2016
    54. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    55. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    56. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not Plaque Psoriasis with Tofacitinib in a Young Woman Acta dermato-venereologica · 2016
    57. Efficacy of Tofacitinib in Treatment of Alopecia Universalis in Two Patients Journal of the European Academy of Dermatology and Venereology · 2016
    58. Familial Aggregation of Alopecia Areata Journal of the American Academy of Dermatology · 2016
    59. An Open-Label Pilot Clinical Trial of the JAK Inhibitor Tofacitinib for Alopecia Areata Journal of Investigative Dermatology · 2016
    60. Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers Experimental Dermatology · 2016
    61. Transient Efficacy of Tofacitinib in Alopecia Areata Universalis Case Reports in Dermatology · 2016
    62. Alopecia Areata and Health-Related Quality of Life: A Systematic Review and Meta-Analysis British Journal of Dermatology · 2016
    63. Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata Journal of the American Academy of Dermatology · 2015
    64. Topical Ruxolitinib for the Treatment of Alopecia Universalis JAMA dermatology · 2015
    65. Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated with Alopecia Universalis JAMA Dermatology · 2015
    66. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015
    67. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    68. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014
    69. Alopecia in the United States: Outpatient Utilization and Common Prescribing Patterns Journal of the American Academy of Dermatology · 2007

    Related research 3

    1. Resistant Alopecia Areata Treated with Tofacitinib International Journal of Trichology · 2022
    2. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018
    3. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016